American Journal of Kidney Diseases
Volume 49, Issue 3 , Pages 352-355 , March 2007

In the Literature: On Clinical Performance Measures and Outcomes Among Hemodialysis Patients

  • Patrick S. Parfrey, MD, FRCP(C)

      Affiliations

    • Corresponding Author InformationAddress reprint requests to Patrick S. Parfrey, MD, FRCP(C), University Research Professor, Memorial University, St. John’s, Newfoundland, Canada A1B 3V6.

References 

  1. U.S. Renal Data System. 2003 USRDS Annual Data Report: Atlas of End-Stage Renal Disease in the United States. Bethesda, MD: The National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2003;
  2. Rocco MV, Frankenfield DL, Hopson SD, McClellan WM. Relationship between clinical performance measures and outcomes among patients receiving long-term hemodialysis. Ann Intern Med. 2006;14:512–519
  3. Foley RN, Parfrey PS, Harnett JD, Kent GM, Murray DC, Barre PE. Hypoalbuminemia, cardiac morbidity, and mortality in end-stage renal disease. J Am Soc Nephrol. 1996;7:728–736
  4. Foley RN, Parfrey PS, Harnett JD, Kent GM, Murray DC, Barre PE. The impact of anemia on cardiomyopathy, morbidity, and mortality in end-stage renal disease. Am J Kidney Dis. 1996;28:53–61
  5. Collins AJ. Influence of target hemoglobin in dialysis patients on morbidity and mortality. Kidney Int (Suppl). 2002;80:44–48
  6. Port FK, Ashby VB, Dhingra RK, Roys E, Wolfe RA. Dialysis dose and body mass index are strongly associated with survival in hemodialysis patients. J Am Soc Nephrol. 2002;13:1061–1066
  7. Besarab A, Bolton WK, Browne JK, et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med. 1998;339:584–590
  8. Parfrey PS, Foley RN, Wittreich BH, Sullivan DJ, Zagari MJ, Frei D. Double-blind comparison of full and partial anemia correction in incident hemodialysis patients without symptomatic heart disease. J Am Soc Nephrol. 2005;16:2180–2189
  9. Drüeke TB, Locatelli F, Clyne N, et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med. 2006;355:2071–2084
  10. Singh AK, Szczech L, Tang KL, et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med. 2006;355:2085–2098
  11. Eknoyan G, Beck GJ, Cheung AK, et al. Effect of dialysis dose and membrane flux in maintenance dialysis. N Eng J Med. 2002;347:2010–2019
  12. Greene T, Daugirdas J, Depner T, et al. Association of achieved dialysis dose with mortality in the hemodialysis study: an example of “dose targeting in bias”. J Am Soc Nephrol. 2005;16:3371–3380
  13. Lowrie EG, Laird NM, Parker TF, Sargent JA. Effect of the hemodialysis prescription on patient morbidity: report from the National Co-operative Dialysis Study. N Eng J Med. 1981;305:1176–1181
  14. Canadian Erythropoietin Study Group. Association between recombinant human erythropoietin and quality of life and exercise capacity of patients receiving hemodialysis. BMJ. 1990;300:573–578
  15. Woods JD, Turenne MN, Strawderman RL, et al. Vascular access survival among incident hemodialysis patients in the United States. Am J Kidney Dis. 1997;30:50–57
  16. Hodgkinson KA, Parfrey PS, Bassett AS, et al. The impact of implantable cardioverter-defibrillator therapy on survival in autosomal-dominant arrhythmogenic right ventricular cariomyopathy (ARVD5). J Am Coll Cardiol. 2005;45:400–408

 Support: Funding received from Amgen, Ortho, and Roche for research on erythropoietin agents. Potential conflicts of interest: None.

PII: S0272-6386(07)00118-7

doi: 10.1053/j.ajkd.2007.01.019

American Journal of Kidney Diseases
Volume 49, Issue 3 , Pages 352-355 , March 2007

Article Tools

* Image Usage & Resolution